ESC Premium Access

Introduction - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Congress Session

About the speaker

Professor Lars Ryden

Karolinska Institute, Stockholm (Sweden)
32 presentations
0 follower

3 more presentations in this session

Results from the LEADER cardiovascular outcomes trial.

Speaker: Doctor M. Husain (Toronto, CA)

Thumbnail

Translating trials into practice – Clinical implications .

Speaker: Professor M. Pfeffer (Boston, US)

Thumbnail

Interactive discussions - GLP-1 receptor agonists and CV risk management in type 2 diabetes: a new treatment paradigm?

Speaker: Professor L. Ryden (Stockholm, SE) Doctor M. Husain (Toronto, CA) Professor M. Pfeffer (Boston, US)

Thumbnail

Access the full session

GLP-1 receptor agonists and cardiovascular risk management in type 2 diabetes: a new treatment paradigm?

Speakers: Professor L. Ryden, Doctor M. Husain, Professor M. Pfeffer, Professor L. Ryden, Doctor M. Husain...
Thumbnail

About the event

Image

ESC CONGRESS 2017

26 August - 30 August 2017

Sessions Presentations

This platform is supported by

logo Novo Nordisk